Prof Bieber opened the symposium by explaining that there has been a revolution in the management of patients with moderate-to-severe atopic dermatitis (AD) since the approval of the first biologic, dupilumab, in 2017.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.